We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
186 hedge funds and large institutions have $766M invested in ANI Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 73 increasing their positions, 51 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
43% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 51
16% more capital invested
Capital invested by funds: $662M → $766M (+$104M)
8% more funds holding
Funds holding: 172 → 186 (+14)
4% more ownership
Funds ownership: 61.09% → 65.09% (+4%)
15% less call options, than puts
Call options by funds: $1.65M | Put options by funds: $1.96M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
186
Holders Change
+14
Holders Change %
+8.14%
% of All Funds
2.95%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
30
Increased
73
Reduced
51
Closed
16
Calls
$1.65M
Puts
$1.96M
Net Calls
-$302K
Net Calls Change
-$560K
Top Buyers
| 1 |
BlackRock
New York
|
+$21.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$12.7M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.4M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$6.29M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.76M |
